• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.

作者信息

Bates T R, Blumenthal H P, Pieniaszek H J

出版信息

Clin Pharmacol Ther. 1977 Dec;22(6):917-27. doi: 10.1002/cpt1977226917.

DOI:10.1002/cpt1977226917
PMID:21768
Abstract

The concentrations of sulfapyridine (SP) and N4-acetylsulfapyridine (AcSP) in the plasma and saliva of 5 healthy male adults (3 slow and 2 rapid acetylators) were determined as a function of time after a single 2.0-gm oral dose of sulfasalazine (salicylazosulfapyridine). SP absorption commenced 3.5 to 6 hr after sulfasalazine administration and occurred slowly (apparent absorption t1/2s ranged from 1.6 to 5 hr) irrespective of acetylator phenotype. Appreciable differences existed between slow and rapid acetylators with respect to the biologic t1/2 and total body clearance of SP. SP concentrations in the saliva correlated well with those in the plasma. The saliva:plasma concentration ratio for SP was 0.559 +/- 0.027 (mean of 5 subjects +/- SE) and was dependent of plasma concentration and saliva pH. The mean saliva:plasma concentration ratio for AcSP was lower (0.246 +/- 0.056), consistent with the pH-partition hypothesis, and showed considerably more intrasubject and intersubject variation than the ratio for SP. These findings suggest that measurement of SP concentrations in the saliva may be a convenient, noninvasive method for monitoring indirectly the steady-state plasma (serum) concentrations of SP in patients with ulcerative colitis or Crohn's disease who are receiving sulfasalazine.

摘要

相似文献

1
Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
Clin Pharmacol Ther. 1977 Dec;22(6):917-27. doi: 10.1002/cpt1977226917.
2
Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
Res Commun Chem Pathol Pharmacol. 1976 Sep;15(1):183-9.
3
Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.溃疡性结肠炎和克罗恩病患者中磺胺吡啶的乙酰化多态性
Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):514-20. doi: 10.1002/cpt1975185part1514.
4
Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.唾液:对正常志愿者和炎症性肠病患者给予柳氮磺胺吡啶后磺胺吡啶的唾液与血浆浓度关系。
Br J Clin Pharmacol. 1980 Jan;9(1):91-4. doi: 10.1111/j.1365-2125.1980.tb04802.x.
5
Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: effects of disease activity, acetylator phenotype, and age.炎症性肠病患儿中柳氮磺胺吡啶代谢产物的药代动力学:疾病活动度、乙酰化表型和年龄的影响
Pediatr Pharmacol (New York). 1982;2(4):323-33.
6
Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.来自市售肠溶包衣和未包衣柳氮磺吡啶片剂的磺胺吡啶的相对全身可用性。
J Clin Pharmacol. 1979 Jan;19(1):39-45. doi: 10.1002/j.1552-4604.1979.tb01615.x.
7
Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake.
Clin Pharmacol Ther. 1995 Apr;57(4):461-70. doi: 10.1016/0009-9236(95)90217-1.
8
Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
Scand J Gastroenterol. 1986 Aug;21(6):693-700. doi: 10.3109/00365528609011102.
9
Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.慢性肠道疾病患者使用柳氮磺胺吡啶治疗期间乙酰化表型、血浆磺胺吡啶水平与不良反应之间的关系。
Isr J Med Sci. 1990 Jan;26(1):31-4.
10
Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.柳氮磺胺吡啶和磺胺吡啶对溃疡性结肠炎患者直肠给药和口服给药后的比较药代动力学
Eur J Clin Pharmacol. 1984;26(2):275-7. doi: 10.1007/BF00630300.

引用本文的文献

1
Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.人体中某些磺胺类药物乙酰化表型及药代动力学的测定
Clin Pharmacokinet. 1980 May-Jun;5(3):274-94. doi: 10.2165/00003088-198005030-00006.
2
Azo reduction of sulphasalazine in healthy volunteers.
Br J Clin Pharmacol. 1982 Sep;14(3):395-8. doi: 10.1111/j.1365-2125.1982.tb01997.x.
3
Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
Eur J Clin Pharmacol. 1981;21(3):243-50. doi: 10.1007/BF00627927.
4
Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.唾液:对正常志愿者和炎症性肠病患者给予柳氮磺胺吡啶后磺胺吡啶的唾液与血浆浓度关系。
Br J Clin Pharmacol. 1980 Jan;9(1):91-4. doi: 10.1111/j.1365-2125.1980.tb04802.x.
5
Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.柳氮磺胺吡啶、其代谢产物及其他5-氨基水杨酸前体药物的临床药代动力学。
Clin Pharmacokinet. 1985 Jul-Aug;10(4):285-302. doi: 10.2165/00003088-198510040-00001.
6
Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin.
Pharm Res. 1989 Dec;6(12):1067-72. doi: 10.1023/a:1015938706685.
7
Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).用于治疗胃肠道疾病的药物的临床药代动力学(第二部分)。
Clin Pharmacokinet. 1990 Aug;19(2):94-125. doi: 10.2165/00003088-199019020-00002.
8
The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.
Clin Pharmacokinet. 1992 Oct;23(4):311-20. doi: 10.2165/00003088-199223040-00006.
9
Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.
J Pharmacokinet Biopharm. 1979 Feb;7(1):69-85. doi: 10.1007/BF01059442.